Efficacy and safety of dose-optimization strategies for CDK4/6 inhibitors in HR+/HER2-advanced breast cancer:a Meta-analysis
10.12173/j.issn.1005-0698.202504058
- VernacularTitle:CDK4/6抑制剂剂量优化策略在HR+/HER2-晚期乳腺癌中疗效与安全性的Meta分析
- Author:
Yating ZHENG
1
;
Songling LIU
;
Liyan ZHOU
Author Information
1. 青岛市市立医院药剂科(山东青岛 266000)
- Publication Type:Journal Article
- Keywords:
CDK4/6 inhibitor;
HR+/HER2-breast cancer;
Dose-optimization;
Meta-analysis
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(7):795-805
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically review the efficacy and safety of reduced versus standard doses of CDK4/6 inhibitors in patients with HR+/HER2-advanced breast cancer.Methods PubMed,Web of Science,Cochrane Library,Embase,CNKI,WanFang Data,VIP,databases were electronically searched to collect randomized controlled trials(RCTs)on HR+/HER2-advanced breast cancer patients treated with reduction of CDK4/6 inhibitor dose and standard dose from inception to April 1,2025.Two reviewers independently screened the literature,extracted data,and assessed the risk of bias of the included studies.Meta-analysis was performed using RevMan 5.1 software.Results A total of 14 RCTs involving 4,958 patients were included.The results of Meta-analysis showed that there was no statistically significant difference in PFS[HR=1.01,95％CI(0.92,1.11),P=0.81]and OS[HR=0.78,95％CI(0.52,1.18),P=0.25]in the dose-reduced group and the standard dose group,while ORR[RR=0.83,95％CI(0.71,0.96),P=0.01]and incidence of grade 3 and above neutropenia[RR=0.42,95％CI(0.21,0.85),P=0.02]in the dose-reduced group were significantly better than those in the standard dose group.Conclusions Current evidence shows that the dose reduction of CDK4/6 inhibitors can considerably reduce the incidence of grade 3 and above neutropenia without affecting PFS and OS.
